Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Associate Director, Customer Journey plays a pivotal role in orchestrating the end-to-end customer experience throughout the patient journey. From diagnosis, to the initial treatment decision-making process involving patients, caregivers, and healthcare professionals, to treatment initiation and maintenance, this position integrates expertise from Multichannel Marketing (MCM), Patient Support, Market Access, and Marketing. Reporting to the Senior Director of Multichannel Marketing & Patient Support, this role provides strategic direction and executes initiatives to enhance the overall customer experience and drive business results.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) based in Toronto, is a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), which touts a storied reputation more than 300 years in the making. Our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTP-C’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in Canadian markets. The company handles sales, marketing, market access, and business development functions. MTP-C is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness and currently seeking motivated professionals who share our vision of scientific excellence, innovation, and unwavering dedication to improving the lives of patients.   The Manager, Market Access will develop and implement integrated strategies to engage key stakeholders that may be involved in pricing and access of the organization’s current and future therapeutic areas. This incumbent will be accountable for responsibilities spanning from pre-launch to the mature phase of products that include collaborating with Patented Medicine Price / Drug Review Boards, Pricing Guidelines filing and reporting, Drug and Health Technology Agencies, Pharmaceutical Alliances and individual provinces customers and processes.   This incumbent will also collaborate cross-functionally with Marketing, Regulatory, Medical Affairs, Patient Support & Patient Advocacy, Sales and provide direct support to the Director of Pricing, Market Access & Government Affairs in the development and implementation of brands patient-driven access strategies.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS), and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Senior Director, Portfolio Management will lead the strategic planning and execution of global R&D portfolio.  The incumbent is responsible for overseeing the progress of drug development projects, optimizing resource/R&D investment allocation with sophisticated prioritization methodology, and ensuring alignment with the company's strategic objectives.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS), and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Director, Government Accounts will be responsible for the development and implementation of government channel strategy and tactics designed to secure, maintain and expand appropriate access and reimbursement for all MTPA products. The incumbent will be responsible for strategic imperatives and tactical planning for targeted government channels: CMS, Medicare Part B MAC’s, VA, DOD and Tricare East and West.     This position will facilitate access and reimbursement for MTPA products and insure coordinated/targeted pull through with the field Sales and Marketing.  The Director, Government Accounts will maintain a high level of collaboration and integration with Marketing, Sales, Product Development, Medical, Legal, Strategic Reimbursement, Training, Finance and Senior Leadership.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson’s (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Global Development Office Coordinator provides coordination and administrative support for the Head of Global Development and other departments as required. The position will contribute to all documentation activities to support policies and procedures and overall improvements within the Global Development Office. 

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson’s (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   Provides administrative support for assigned individual(s) and/or department(s).

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson’s (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Drug Safety Aggregate Reports will function as the overall project manager for the development and finalization of assigned key safety documents such as Development Safety Update Reports (DSURs), Periodic Benefit Risk Evaluation Reports (PBRERs), and Risk Management Plans (RMPs). The individual will also maintain and manage agreement and contract updates related to drug safety vendors and support the logistical management of global safety governance escalation meetings including agenda creation with the application of good documentation practice.   The Manager, Drug Safety Aggregate Reports collaborates with internal and external stakeholders managing data information and exchange between all parties involved. The incumbent leads stakeholder meetings and troubleshoots and mitigates issues throughout the development process of each key deliverable.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson’s (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Drug Safety will support signal detection activities and medical analyses to support evaluation and characterization of safety topics for products working closely with Drug Safety Global Safety Team (GST) Chair (Medical Director). The Manager, Drug Safety will perform signal management process activities for assigned products, including combination products (drug and device) including signal tracking, safety data analysis, and presenting in the GST governance meetings. Incumbent will perform the review of worldwide medical/scientific literature to identify information applicable for inclusion in aggregate reports and for potential safety signals, and author safety aggregate reports as needed. The Manager, Drug performs medical analyses for risk characterization to develop Risk Management Plans (RMPs). The Manager will also draft responses for regulatory authority inquires on aggregate reports and author applicable information and data for marketing applications [New Drug Applications (NDA), New Drug Submission (NDS)], Amendments, Supplements, Safety Reports, and general correspondence for all assigned.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS), and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Associate Director, Medical Affairs, Movement Disorder/Parkinson’s Disease will be responsible for supporting the development and implementation of the Medical Scientific Strategy for Parkinson’s disease in the US. This includes supporting and leading projects related to pre-approval and post-approval medical activities in Parkinson’s disease (ND0612) and related diseases in close collaboration with cross-functional colleagues. The Associate Director, Medical Affairs will serve as a subject matter expert, be scientifically and clinically focused, and consider the needs of the medical community, patient communities, and other constituencies in compliance with applicable laws and regulations and company policies.   Drawing on disease state expertise and product knowledge, the Associate Director will support the Senior Director, Medical Affairs in representing Medical Affairs and MTPA in external settings such as medical congresses or company-sponsored scientific advisory meetings. In addition, the Associate Director may be asked to represent the Medical Affairs team on cross-functional projects and meetings, such as promotional and non-promotional program review committees, offer medical input upon request to assist in development of promotional materials, and on other internal activities leveraging her/his scientific and clinical expertise in Parkinson’s disease/Movement Disorders as well as knowledge of best practices in Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Medical Science Liaison provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the Medical Science Liaison supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging US and global organization, the Medical ScienceLiaison  will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The Medical Science Liaison will report directly to the Field Medical Director, Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Medical Science Liaison provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the Medical Science Liaison supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging US and global organization, the Medical ScienceLiaison  will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The Medical Science Liaison will report directly to the Field Medical Director, Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Director, National Sales will establish and execute a plan to meet and exceed sales expectations of edaravone (MCI-186), an innovative solution approved in Japan and granted Orphan Drug status by the FDA for patients suffering from Amyotrophic Lateral Sclerosis (ALS), and for future launch brands and product acquisitions. As part of a commercial organization, the incumbent will play a critical role in shaping the sales function and strategy.   The Director, National Sales will hire, develop, and lead the field sales organization and will work effectively within the broader team to ensure seamless alignment and execution of the broader organization goals and launch plan objectives.   The position will require 50% – 60% travel and must be based within 1 hour of a major airport.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) based in Toronto, is a wholly owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), which touts a storied reputation more than 300 years in the making. Our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTP-C’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in Canadian markets. The company handles sales, marketing, market access, and business development functions. MTP-C is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness and currently seeking motivated professionals who share our vision of scientific excellence, innovation, and unwavering dedication to improving the lives of patients.   The Medical Science Liaison (MSL) provides a vital role to the organization by bridging internal strategy with external medical insights. Through interactions with the healthcare community, the MSL supports disease awareness activities, participates in scientific exchange, and obtains valuable information regarding unmet medical needs and current treatment paradigms to help guide executive decisions. As part of an emerging Canadian and global organization, the MSL will also make significant contributions to processes, procedures, and best practices within the developing organization, serve as a medical resource to healthcare providers, clinical investigators and clinical study sites, and healthcare decision makers regarding the organization’s investigational and marketed products, and support product commercialization. The MSL will report directly to the Medical Director, Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.